Tag: 18

Boise, Idaho, July 06, 2026 (GLOBE NEWSWIRE) -- Idaho Copper Corporation (“Idaho Copper” and the “Company”) (NYSE American: COPR, COPR WS), a critical minerals developer advancing the flagship CuMo copper-molybdenum-silver project in Idaho, today announced the closing of its underwritten public offering of shares of its common stock and warrants at a public offering price of $4.85 per share and accompanying warrant for gross proceeds of approximately $18,000,000, before deducting underwriting discounts and offering expenses. In addition, Idaho Copper has granted the underwriters a 45-day option to purchase up to an additional 556,800 shares of common stock and/or warrants to cover over-allotments at the public offering price, if any. The offering also included the purchase by the underwriters of 556,800 warrants in connection with the partial exercise by the underwriters of their over-allotment option.

AMF Regulated Information
Châtillon, France, July 6, 2026

Regulated information
Paris, 6 July 2026

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4